HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.